<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2831">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051361</url>
  </required_header>
  <id_info>
    <org_study_id>2013-CLOBES-EL-41</org_study_id>
    <nct_id>NCT02051361</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy Following Stent Implantation</brief_title>
  <acronym>Anti-Clot</acronym>
  <official_title>Open Label, Non Interventional, Multi-center, Observational Study to Assess the Antiplatelet Treatment Pre and Post-operatively of Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elpen Pharmaceutical Co. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elpen Pharmaceutical Co. Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery stents, particularly drug-eluting stents (DES), are used in the majority of&#xD;
      patients who undergo percutaneous coronary intervention (PCI) to improve symptoms in patients&#xD;
      with obstructive coronary artery disease. They function both to prevent abrupt closure of the&#xD;
      stented artery soon after the procedure as well as to lower the need for repeat&#xD;
      revascularization compared to balloon angioplasty alone . Stent restenosis and stent&#xD;
      thrombosis are potential complications of coronary artery stenting; their incidence is&#xD;
      highest in the first year after PCI. Stent restenosis, which occurs more frequently with bare&#xD;
      metal stents (BMS) than DES, may occasionally present as an acute myocardial infarction (MI).&#xD;
      Stent thrombosis is an uncommon but serious complication that often presents as death and is&#xD;
      almost always accompanied by MI, usually with ST-segment elevation. Patients are commonly&#xD;
      treated with dual antiplatelet therapy (DAPT) for the recommended duration for the particular&#xD;
      stent. DAPT (aspirin plus platelet P2Y12 receptor blocker) and significantly lowers the risk&#xD;
      of stent thrombosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New Guidance on Antiplatelet Therapy After Stenting: Clinical Advisory, Kirsten E.&#xD;
      Fleischmann, MD, MPH reviewing Grines CL et al. Circulation 2007 Feb 13. An expert panel&#xD;
      recommends 12 months of therapy after placement of drug-eluting stents. Aspirin and&#xD;
      clopidogrel are commonly prescribed after placement of both bare metal stents and&#xD;
      drug-eluting stents. However, recent concerns about stent thrombosis (Journal Watch Jan 4&#xD;
      2007) have led experts from multiple groups, including the American Heart Association and the&#xD;
      American College of Cardiology, to issue an advisory on preventing premature discontinuation&#xD;
      of dual antiplatelet therapy. Based on a review of the literature, the experts offer&#xD;
      observations and recommendations including the following:&#xD;
&#xD;
        -  Dual antiplatelet therapy with aspirin and a thienopyridine such as clopidogrel reduces&#xD;
           cardiac events after coronary stenting.&#xD;
&#xD;
        -  Premature discontinuation of these agents greatly increases the risk for stent&#xD;
           thrombosis and associated clinical events such as myocardial infarction and death.&#xD;
&#xD;
        -  Patients should receive 12 months of dual antiplatelet therapy after placement of&#xD;
           drug-eluting stents.&#xD;
&#xD;
        -  Elective surgery associated with a significant risk for bleeding should be postponed&#xD;
           until an appropriate course of dual antiplatelet therapy (i.e., 1 month for bare metal&#xD;
           stents and 12 months for drug-eluting stents) has been completed.&#xD;
&#xD;
        -  Patients' ability to comply with prolonged dual antiplatelet therapy and their need for&#xD;
           subsequent invasive procedures should be considered when choosing the type of stent.&#xD;
&#xD;
        -  Patients and their other providers should consult with the patient's cardiologist before&#xD;
           stopping dual therapy.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary endpoint - Outcome Measures:&#xD;
&#xD;
      1. Major Cardiovascular events at 1, 3, 6, 12 months after study enrolment&#xD;
&#xD;
        -  All Death,&#xD;
&#xD;
        -  Cardiac death,&#xD;
&#xD;
        -  Myocardial infarction,&#xD;
&#xD;
        -  Stroke,&#xD;
&#xD;
        -  Target vessel revascularization&#xD;
&#xD;
        -  Bleeding event&#xD;
&#xD;
        -  In-stent restenosis (ISR)&#xD;
&#xD;
             -  Angiographical Determination of Binary Stenosis Rate (defined as diameter stenosis&#xD;
                of at least 50 % in the stent and / or persistent area, 6, 9, 12 months after stent&#xD;
                implantation) The angiographical determination of the degree of stenosis, defined&#xD;
                as percentage diameter stenosis in the stent and /or persistent area, 6 and 12&#xD;
                months after stent implantation.&#xD;
&#xD;
             -  The angiographical determination of the minimal lumen diameter in the stent and /&#xD;
                or persistent area, 6 months after stent implantation.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  Description of any reported AE/ SAE per study subgroup.&#xD;
&#xD;
        -  Description of any missing doses per study subgroup.&#xD;
&#xD;
      Study Medication:&#xD;
&#xD;
      Category: ADP-P2Y12 interaction blokers&#xD;
&#xD;
        -  Clopidogrel (Clovelen®)&#xD;
&#xD;
        -  Dosage: As per Clopidogrel (Clovelen®) SmPC&#xD;
&#xD;
      Study Concomitant Medication:&#xD;
&#xD;
      Aspirin. DAT = Dual antiplatelet therapy consists of aspirin add on clopidogrel&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Major Adverse Cardiac Events (MACEs)</measure>
    <time_frame>6 months</time_frame>
    <description>All Death,&#xD;
Cardiac death,&#xD;
Myocardial infarction,&#xD;
Stroke,&#xD;
Target vessel revascularization (TVR)&#xD;
Bleeding event&#xD;
In-stent restenosis (ISR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of missed daily doses</measure>
    <time_frame>6 months</time_frame>
    <description>Compliance to antiplatelet treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">900</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Coronary Syndrome</condition>
  <condition>Angina, Unstable</condition>
  <arm_group>
    <arm_group_label>Clopidogrel treated patients</arm_group_label>
    <description>Patients pre and post operatively following stent implantation treated with clopidogrel and aspirin</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients on clopidogrel treatment following stent implantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients in whom planned or unplanned stent implantation&#xD;
&#xD;
          -  Ages Eligible for Study: 18 Years and older&#xD;
&#xD;
          -  Genders Eligible for Study: Both&#xD;
&#xD;
          -  Acute coronary syndrome&#xD;
&#xD;
          -  ST-segment elevation MI (STEMI)&#xD;
&#xD;
          -  non ST-segment elevation MI (STEMI)&#xD;
&#xD;
          -  Stable angina pectoris and or/ documented myocardial ischemia&#xD;
&#xD;
          -  Instable angina pectoris and or/ documented myocardial ischemia&#xD;
&#xD;
          -  De-novo stenosis of coronary artery with a degree of stenosis between 50% and 99%,&#xD;
             that is accessible to PTCA&#xD;
&#xD;
          -  Patients on pre-defined group of clopidogrel treatment during and after DES&#xD;
             implantation&#xD;
&#xD;
          -  Willingness and ability to adhere to the study conditions&#xD;
&#xD;
          -  Written informed consent after patient information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known severe arrhythmias that necessitate a long term antiarrhythmic therapy&#xD;
&#xD;
          -  Pericarditis&#xD;
&#xD;
          -  Intracardiac thrombus&#xD;
&#xD;
          -  Bacterial endocarditis&#xD;
&#xD;
          -  Patients with contraindication for aortocoronary bypass operation,&#xD;
&#xD;
          -  Contraindication to antiplatelet therapy&#xD;
&#xD;
          -  Non-cardiac co-morbid conditions that may result in protocol non-compliance (per site&#xD;
             investigator's medical judgment).&#xD;
&#xD;
          -  Bleeding diathesis&#xD;
&#xD;
          -  Thrombocytopenia (&lt;150 000/mm3)&#xD;
&#xD;
          -  Recent (&lt;6 months) gastrointestinal bleeding&#xD;
&#xD;
          -  Recent stroke within 6-months&#xD;
&#xD;
          -  Concurrent organ damage (creatinine level &gt; 2.0mg/dL or AST and ALT &gt; 3 times upper&#xD;
             normal reference values)&#xD;
&#xD;
          -  Patients with left main stem stenosis (&gt;50% by visual estimate)&#xD;
&#xD;
          -  History of allergy to aspirin&#xD;
&#xD;
          -  Inability, to understand sense and purpose of the study&#xD;
&#xD;
          -  Patients not willing to keep the conditions of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sotirios Patsilinakos, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Agia Olga Konstantopoulion hospital of Athens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolaos Kafkas, MD Cardiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>KAT Hospital of Athens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KAT Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>http://circ.ahajournals.org/content/117/2/261.full.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/17224480</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19044176</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.ima.org.il/FilesUpload/IMAJ/0/43/21642.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.scielo.br/pdf/jvb/v7n3/v7n3a10.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DAT = Dual Antiplatelet Treatment</keyword>
  <keyword>Major Cardiac Adverse Events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

